Celerion, a global leader in early clinical research services, offers a unique combination of medical expertise, clinical operations experience and scientific excellence that gives our clients the confidence to make fast, accurate decisions about their drug development path. Our services include comprehensive clinical development services from Phase I-III, including patient dose response studies, cardiovascular safety and product labeling studies. In addition, Celerion offers statistics, data management and biostatistics, and bioanalytical services. Our founding mission is to help our clients get their drugs to market quickly, so that they touch the lives of our family, friends and people in need around the world. For more information please visit www.celerion.com.

1.Full Service Global Clinical Development

Today, Celerion is one of the world's leading CROs in early phase research, working with biopharmaceutical companies and patients around the globe. We are more than 1,000 full-time scientific and medical personnel with the skills to design, execute, and interpret complex clinical studies, while upholding the highest standard of ethics. Our facilities offer over 600 beds and are among the most extensive in the industry, and our clinical research professionals have extensive experience and expertise to help you transition through Proof of Concept and beyond across North America, Europe, and Asia. Using these resources, we help get your product into the world faster, so you can start making a difference in people’s lives.

2.Expertise and Key Therapeutic Area

3.Global Bioanalytical Service

Our laboratories focus on science, compliance and speed to deliver high-quality data. Our state-of-the-art automated facilities in Zürich, Switzerland and Lincoln, Nebraska USA, are among the most respected laboratories in the industry. We apply our 40+ years of experience to exceed your bioanalytical expectations from method development and validation through rapid sample analysis supporting discovery through late stage clinical studies. Our 100+ scientists, armed with the latest bioanalytical technologies, are committed to solving your challenges with scientific excellence. We perform, on average, over a 100 method validations per year in small and large molecules as well as immunogenicity. Through continuous improvement in quality and compliance processes and systems, and investment in the latest automation technologies, Celerion has the global capacity to analyze more than 600,000 samples per year, providing industry-leading turnaround time.